The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Stelara was produced by Johnson & Johnson.
J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.
J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing
This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.
First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three
showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...